Literature DB >> 30333416

Dabigatran-induced Esophageal Ulcer at a Natural Constriction.

Sho Sasaki1, Jun Nishikawa2, Atsushi Goto3, Isao Sakaida3.   

Abstract

Entities:  

Keywords:  dabigatran; esophageal ulcer

Year:  2018        PMID: 30333416      PMCID: PMC6443540          DOI: 10.2169/internalmedicine.1618-18

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
A 48-year-old man with atrial fibrillation who had been taking dabigatran for 12 months experienced chest discomfort. Esophagogastroduodenoscopy (EGD) revealed an ulcerative lesion in the thoracic esophagus that was compressed by the left bronchus, which healed spontaneously two months later. Five months thereafter, he felt throat discomfort. EGD revealed a semicircular ulcer at the esophageal orifice (Picture 1). The patient usually took dabigatran without water, which allowed the dabigatran to remain abnormally long in the natural constriction of the esophagus, as evidenced by progression of local mucosal injury. After we instructed the patient on proper dabigatran administration, the ulcer healed and has not relapsed for 12 months (Picture 2). Tartaric acid excipient in dabigatran possibly caused the mucosal injury. Characteristics of dabigatran-induced esophagitis are reported as longitudinally sloughing casts in the distal esophagus (Picture 3) (1,2), but our patient's ulcer was located in the esophageal orifice. Clinicians need to instruct patients to take dabigatran with sufficient water in order to avoid ulcer recurrence.
Picture 1.
Picture 2.
Picture 3.
The authors state that they have no Conflict of Interest (COI).
  2 in total

1.  Exfoliative esophagitis and esophageal ulcer induced by dabigatran.

Authors:  M Okada; K Okada
Journal:  Endoscopy       Date:  2012-03-06       Impact factor: 10.093

2.  Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics.

Authors:  Yosuke Toya; Shotaro Nakamura; Kazumitsu Tomita; Nozomi Matsuda; Keinosuke Abe; Yukito Abiko; Shunsuke Orikasa; Risaburo Akasaka; Toshimi Chiba; Noriyuki Uesugi; Tamotsu Sugai; Takayuki Matsumoto
Journal:  J Gastroenterol Hepatol       Date:  2016-03       Impact factor: 4.029

  2 in total
  1 in total

1.  Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.

Authors:  Nashid Farhan; Rodrigo Cristofoletti; Sumit Basu; Sarah Kim; Karthik Lingineni; Sibo Jiang; Joshua D Brown; Lanyan Lucy Fang; Lawrence J Lesko; Stephan Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.